Not on air · 2 of 3 networks checked
Rezon Bio
- rezonbio.com
- PL
- 726 employees
Rezon Bio’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 105. Watch Rezon Bio with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksOct 2026 | Checked | Next step |
|---|---|---|---|---|---|
| None recorded | 0 | Checked 29 Oct 2026 | See all 105 ads → | ||
| Meta | Not checked | — | |||
| Recently | 11 | Ads on the Google Ads Transparency Center | Checked 8 Oct 2026 | Collect them with the API → |
Rezon Bio has no live LinkedIn ads. We recorded 11 Google ads on 8 Oct 2026.
Latest ads
- LINKEDIN · IMAGESince 24 Sept 2026
Biologics timeline risk is rarely visible until it's already a problem. Some bottlenecks only become visible once a program is already underway. From batch release responsibilities to technical changes, several factors can influence biologics program timelines. In this Expert Insight, Dr. Ralf Otto, COO at Rezon Bio, highlights five timeline-critical considerations and outlines questions sponsors can ask before committing to a long-term CDMO partnership.
- LINKEDIN · IMAGESince 24 Sept 2026
When should you engage a biologics CDMO? Earlier than you think. Many sponsors begin CDMO selection after a funding round, a Phase I readout or internal budget approval. However, CDMO onboarding has its own timelines. In this article, Dr. Ralf Otto, COO at Rezon Bio, highlights five factors that can influence program timelines and shares questions sponsors can ask during CDMO selection.
- LINKEDIN · IMAGESince 24 Sept 2026
Not all timeline risks are obvious. Raw material qualification, batch release responsibilities, equipment readiness and project management transparency can all affect biologics program timelines. In this Expert Insight, Dr. Ralf Otto, COO at Rezon Bio, highlights five timeline-critical aspects to consider when evaluating a biologics CDMO and shares questions sponsors can ask before committing to a long-term partnership.
- LINKEDIN · IMAGESince 24 Sept 2026
Some delays begin long before manufacturing starts. Raw material qualification, batch release responsibilities and equipment readiness are just some of the factors that can influence biologics program timelines. In this article, Dr. Ralf Otto, COO at Rezon Bio, highlights five timeline-critical considerations and shares questions sponsors can ask during CDMO selection.
- LINKEDIN · IMAGESince 24 Sept 2026
When should you engage a biologics CDMO? Earlier than you think. Many sponsors begin CDMO selection after a funding round, a Phase I readout or internal budget approval. However, CDMO onboarding has its own timelines. In this article, Dr. Ralf Otto, COO at Rezon Bio, highlights five factors that can influence program timelines and shares questions sponsors can ask during CDMO selection.
- LINKEDIN · IMAGESince 24 Sept 2026
Biologics timeline risk is rarely visible until it's already a problem. Some bottlenecks only become visible once a program is already underway. From batch release responsibilities to technical changes, several factors can influence biologics program timelines. In this Expert Insight, Dr. Ralf Otto, COO at Rezon Bio, highlights five timeline-critical considerations and outlines questions sponsors can ask before committing to a long-term CDMO partnership.
6 of 105 adsSign up to see every Rezon Bio ad, filter by format and date, and get alerts on new ones.
See all 105 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.